RxDoctor Payments Data

Bernice Zierler

Physician Assistant · Teaneck, NJNPI 1477758225

Payments from drug & device makers

$741in general payments, 2019–2025

Across 30 payments — averaging $24.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mylan Specialty L.p.$203
  • AbbVie$85
  • GSK$80
  • Exact Sciences$58
  • Viatris Specialty LLC$57
  • Lilly USA, LLC$49
  • plus $210 from 7 others

What the payments were for

  • Food & beverage$741100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$741 in reported general payments places this provider in the 70th percentile of 2,726 physician assistant providers in New Jersey.

See all physician assistant providers in New Jersey

Medicare billing

Part B allowed, 2024
$120,950
Medicare patients
182
Services billed
4,494

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban38$42,222
JardianceEmpagliflozin32$36,276
OzempicSemaglutide20$24,956
RybelsusSemaglutide16$22,757
XareltoRivaroxaban11$19,108
FarxigaDapagliflozin Propanediol19$19,058
EntrestoSacubitril/Valsartan15$14,329
MounjaroTirzepatide12$14,045
Incruse ElliptaUmeclidinium Bromide20$10,460
LinzessLinaclotide12$10,327
Spiriva RespimatTiotropium Bromide12$10,313
Breo ElliptaFluticasone/Vilanterol14$9,371
Albuterol Sulfate HfaAlbuterol Sulfate133$5,795
VascepaIcosapent Ethyl16$5,557
Enoxaparin Sodium11$4,602

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$16$47,71336 claims
GSKIncruse Ellipta, Breo Ellipta$80$19,83134 claims
Lilly USA, LLCMounjaro$49$14,04512 claims
AbbVieLinzess, Synthroid$85$12,05539 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,726 physician assistant providers in New Jersey.

Other physician assistant in Teaneck

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →